The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
about
Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophyBisphosphonate therapy for children and adolescents with secondary osteoporosisBisphosphonate therapy for osteoporosis in children and adolescents without osteogenesis imperfectaAddition of pamidronate to chemotherapy for the treatment of osteosarcomaGiant osteoclast formation and long-term oral bisphosphonate therapyBisphosphonates: mechanism of action and role in clinical practiceRecent developments in osteogenesis imperfectaBisphosphonate therapy in pediatric patientsThe management of osteoporosis in children.Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.Bisphosphonate treatment for children with disabling conditions.Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challengesGenetic disorders of the skeleton: a developmental approachBone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT.Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.Zoledronic acid improves bone mineral density in pediatric spinal cord injury.Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.Case report: osteogenesis imperfecta Elusive cause of fractures.Modeling the benefits of pamidronate in children with osteogenesis imperfecta.Does the use of a specialised paediatric retrieval service result in the loss of vital stabilisation skills among referring hospital staff?Bisphosphonate treatment of bone diseaseGene therapy approaches for osteogenesis imperfecta.Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonatesOsteoblastic differentiation of bone marrow mesenchymal stromal cells in Bruck SyndromeSystematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritisUnexplained fractures in infancy: looking for fragile bones.Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?The Current and Future Therapies for Human Osteosarcoma.Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta.Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.Pediatric bone density and fracture.Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formationThe effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
P2860
Q24198280-38345916-449B-4D20-9967-D49267A24DFDQ24243298-2DCA6CFE-CE6A-41B3-B3D7-DADECDEF1104Q24244601-30DA055E-84B4-4C78-A83F-74E3A14835CEQ24594269-9157E1A2-CABC-471E-9B92-1C399771E31CQ24626459-A0E2F665-655A-4F3B-9CF6-6009D2034328Q24644708-78486EAA-8D3C-461D-9EDC-6C4363FBAAACQ26781674-E83F8F5F-4443-47C3-88D4-81AEB25A549EQ26830702-CB909B36-7622-46B2-83C0-1D8F8322FA26Q30251490-D4D0E779-23A3-400C-8B55-BCFD100F58D1Q30911013-E4389102-1602-4D76-BFE0-5AFF2195B278Q33680621-683BCF89-7129-4F8D-8988-7465D9E4357BQ33771321-01AE7175-CA1B-42BA-9EE2-0442E42726A4Q33781943-531F5D68-46E8-4D43-BB2D-5A13B8A69901Q33814312-D889F6E1-93F6-4209-9902-4979A853D2E8Q33906292-002E3CD6-3DEA-4411-9058-75B690C57C9FQ34031069-6E1D7796-0DD4-4C5A-816B-059AE3C8EFDDQ34114280-01F89530-B78D-479D-B8EA-243340FEFEB1Q34205600-90DD9B54-6464-40BE-84AA-D5902854D81BQ34476573-55438051-19F0-46FE-AC30-782526B4B36AQ34485618-E8DA846D-4D68-4AE6-87C6-CAF6FC912439Q34682446-344B3E03-9557-44E4-9D4F-B97BBE8F2127Q34816036-4FBF3BD0-61E1-441E-AF65-1E1EF77470ABQ35274303-720B4B15-96BD-466D-9EEF-9358C5A69915Q35283631-345A6F3F-ED2F-4841-96DB-9E6976B846F3Q35629569-35769954-471F-4897-BD6E-A073433C81C0Q35739746-9D240D5B-221B-44C3-99BD-70B6FFF2A4ECQ35752608-D6F78E75-88AF-4DE7-B06B-C177503EA4E3Q35828143-7DFA2097-5CC3-4BA4-93F3-2E4F2DD91336Q36008701-46F2E55C-5A56-49C7-B9BE-ED06BAD8C613Q36153306-BF076A68-68D3-4C37-995C-6E4757CD4B05Q36154523-E30B7AD6-09CE-4435-8FDB-983ACA0727BFQ36155282-FCAE2B0C-8052-4EB1-91DF-9A6C2D215E8BQ36194937-8A128164-BF82-4BF6-9C57-BBBB640D09ADQ36514299-0D39D549-8F10-4918-9D72-B04D310EF5ECQ36735620-91EBB763-0BDD-46EB-9F47-74EDBB2F3AE3Q36839121-CB8D05AC-F1DD-4604-9C71-9866BF83A1CFQ36966222-C455EDB4-BFD8-4411-BA1D-AA188CB63115Q37158425-518224E7-239F-4195-B2C5-43E0DC43CB60Q37166804-3276955F-1DC8-4AAB-BE89-10F9722142B4Q37167038-6C395583-CAF6-4E5B-8F5B-7A7D097C1AE6
P2860
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The effects of intravenous pam ...... with osteogenesis imperfecta.
@ast
The effects of intravenous pam ...... with osteogenesis imperfecta.
@en
The effects of intravenous pam ...... with osteogenesis imperfecta.
@nl
type
label
The effects of intravenous pam ...... with osteogenesis imperfecta.
@ast
The effects of intravenous pam ...... with osteogenesis imperfecta.
@en
The effects of intravenous pam ...... with osteogenesis imperfecta.
@nl
prefLabel
The effects of intravenous pam ...... with osteogenesis imperfecta.
@ast
The effects of intravenous pam ...... with osteogenesis imperfecta.
@en
The effects of intravenous pam ...... with osteogenesis imperfecta.
@nl
P2093
P2860
P356
P1476
The effects of intravenous pam ...... with osteogenesis imperfecta.
@en
P2093
Francis H Glorieux
Frank Rauch
Horacio Plotkin
Rose Travers
P2860
P304
P356
10.1172/JCI0215952
P407
P577
2002-11-01T00:00:00Z